Frontotemporal Dementia News and Research RSS Feed - Frontotemporal Dementia News and Research

TauRx achieves target enrolment in second LMTX Phase III clinical trial for Alzheimer's disease

TauRx achieves target enrolment in second LMTX Phase III clinical trial for Alzheimer's disease

TauRx Therapeutics Ltd has achieved its target enrolment of 700 subjects with mild Alzheimer's disease into the second of its two Phase III clinical trials of LMTX, a tau aggregation inhibitor, for the treatment of Alzheimer's disease. [More]
Mindfulness training can brighten outlook on life for person with memory loss and caregiver

Mindfulness training can brighten outlook on life for person with memory loss and caregiver

Mindfulness training for individuals with early-stage dementia and their caregivers together in the same class was beneficial for both groups, easing depression and improving sleep and quality of life, reports new Northwestern Medicine study. [More]
Finding suggests that retina acts as type of window to the brain

Finding suggests that retina acts as type of window to the brain

Researchers at the Gladstone Institutes and University of California, San Francisco have shown that a loss of cells in the retina is one of the earliest signs of frontotemporal dementia (FTD) in people with a genetic risk for the disorder-even before any changes appear in their behavior. [More]
New therapeutic strategy to combat common genetic risk factor for ALS, FTD

New therapeutic strategy to combat common genetic risk factor for ALS, FTD

A team of researchers at Mayo Clinic and The Scripps Research Institute in Florida have developed a new therapeutic strategy to combat the most common genetic risk factor for the neurodegenerative disorders amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and frontotemporal dementia (FTD). [More]
Researchers identify pathogenic mechanism common to several neurodegenerative diseases

Researchers identify pathogenic mechanism common to several neurodegenerative diseases

An international team of researchers identified a pathogenic mechanism that is common to several neurodegenerative diseases. The findings suggest that it may be possible to slow the progression of dementia even after the onset of symptoms. [More]
Persons with reduced levels of TREM2 protein at greater risk for neurodegenerative diseases

Persons with reduced levels of TREM2 protein at greater risk for neurodegenerative diseases

Persons with reduced levels of the TREM2 protein could be at greater risk of developing neurodegenerative diseases such as Alzheimer's disease or frontotemporal dementia, according to an international study which included the participation of the Universitat Autònoma de Barcelona and the Sant Pau Biomedical Research Institute. [More]
Increasing clearance of ALS misfolded protein from neurons improves their survival

Increasing clearance of ALS misfolded protein from neurons improves their survival

In work supported by The ALS Association, researchers have shown that increasing the clearance of misfolded protein from neurons improves their survival. The study was published today in the journal Nature Chemical Biology. [More]
New investigational drug can slow memory loss in older Individuals with risk for developing AD in future

New investigational drug can slow memory loss in older Individuals with risk for developing AD in future

A new research study at Rush University Medical Center and Northwestern Medicine is testing whether a new investigational treatment can slow the memory loss caused by Alzheimer's disease. [More]

Novel diagnostic tool helps differentiate between dementia diseases

A new diagnostic tool helps clinicians to differentiate between Alzheimer's disease, frontotemporal dementia and mild cognitive impairment. Presented in the doctoral thesis of MD Miguel ángel Muñoz Ruiz at the University of Eastern Finland, the new method consists of a Disease State Index combining data from multiple sources, and of a Disease State Fingerprint showing the findings in a visual format. [More]
Scientists discover novel protein fragments that may protect against Alzheimer's disease

Scientists discover novel protein fragments that may protect against Alzheimer's disease

The devastating loss of memory and consciousness in Alzheimer's disease is caused by plaque accumulations and tangles in neurons, which kill brain cells. [More]
Mayo Clinic neuroscientists define subtype of Alzheimer's disease

Mayo Clinic neuroscientists define subtype of Alzheimer's disease

Neuroscientists at Mayo Clinic in Florida have defined a subtype of Alzheimer's disease (AD) that they say is neither well recognized nor treated appropriately. [More]
Bristol-Myers Squibb completes acquisition of iPierian

Bristol-Myers Squibb completes acquisition of iPierian

Bristol-Myers Squibb Company and iPierian, Inc. announced today that Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, a class of neurodegenerative diseases associated with the pathological aggregation of Tau protein in the human brain. [More]
New findings shed light on how gene mutation causes motor neurone disease

New findings shed light on how gene mutation causes motor neurone disease

Researchers have discovered a mechanism that may explain how a recently discovered mutation causes two devastating neurological diseases. [More]
New findings shed light on how gene mutation causes motor neurone disease

New findings shed light on how gene mutation causes motor neurone disease

Researchers have discovered a mechanism that may explain how a recently discovered mutation causes two devastating neurological diseases. [More]
Increased brain cell activity boosts protein linked to Alzheimer's disease

Increased brain cell activity boosts protein linked to Alzheimer's disease

Increased brain cell activity boosts brain fluid levels of a protein linked to Alzheimer's disease, according to new research from scientists at Washington University School of Medicine in St. Louis. [More]
Glimmer of hope for Alzheimer’s disease sufferers

Glimmer of hope for Alzheimer’s disease sufferers

Hope may be on its way for sufferers of Alzheimer’s Disease as the Griffith Health Institute seeks participants for new research. [More]

TauRx Therapeutics adds new research centers across U.S. for Alzheimer’s clinical trials

TauRx Therapeutics Ltd, a clinical-stage biopharmaceutical company developing a novel treatment for Alzheimer's disease, has expanded its international clinical trials by adding new research centers across the U.S. [More]
Researchers identify novel therapeutic approach for most frequent genetic cause of ALS

Researchers identify novel therapeutic approach for most frequent genetic cause of ALS

A team of scientists led by researchers from the University of California, San Diego School of Medicine and Ludwig Institute for Cancer Research have identified a novel therapeutic approach for the most frequent genetic cause of ALS, a disorder of the regions of the brain and spinal cord that control voluntary muscle movement, and frontal temporal degeneration, the second most frequent dementia. [More]
Study: Speaking a second language may delay onset of three types of dementias

Study: Speaking a second language may delay onset of three types of dementias

In the largest study on the topic to date, research shows that speaking a second language may delay the onset of three types of dementias. The research is published in the November 6, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
Scientists identify new toxic entity associated with dementia and motor neuron disease

Scientists identify new toxic entity associated with dementia and motor neuron disease

A new toxic entity associated with genetically inherited forms of dementia and motor neuron disease has been identified by scientists at the UCL Institute of Neurology. The toxin is the result of a genetic mutation that leads to the production of RNA molecules which could be responsible for the diseases. The findings are published in the journal Acta Neuropathologica. [More]